에서 실시간으로 운영 중이에요! 자세히 알아보기
69.16 USD
-1.35
1.91%
장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT
프리마켓
시간외 거래
69.40
+0.24
0.35%
1일
-1.91%
5일
5.43%
1개월
4.77%
3개월
8.25%
6개월
77.33%
연초 이후
65.53%
1년
94.05%
5년
8.05%
10년
131.54%
 

소개: Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.

직원 수: 61,100

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 70.5%
중립 23.8%
부정적 5.7%
중립
PRNewsWire
16시간 전
Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma
Expansion into Ohio and Oklahoma for plan year 2027 builds on early success offering employees  CHOICE Arrangements in Indiana in 2026 ST. LOUIS, Oct. 16, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced the expansion of its CHOICE Arrangements benefit program (formerly ICHRA) to employees in Ohio and Oklahoma for plan year 2027.
Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma
긍정적
Seeking Alpha
어제
Centene: The Turnaround Has More Room To Run
Centene Corp. maintains a Buy rating as profitability recovers faster than expected, with Q2 2026 adjusted EPS of $2.51 versus a prior-year loss. CNC raised full-year adjusted EPS guidance to over $4.80, driven by improved Marketplace and Medicare Part D margins, despite a 40% YoY decline in Marketplace membership. Medicaid remains a headwind, with expected 8–9% membership decline in 2026 and regulatory risks from OB3, but management targets margin improvement and breakeven Medicare Advantage in 2027.
Centene: The Turnaround Has More Room To Run
긍정적
Seeking Alpha
어제
Centene Remains A Buy Heading Into Q3
Centene Corporation remains a Buy, supported by operational improvements, disciplined capital management, and a discounted valuation versus sector averages. CNC's Medicaid margins are holding up despite expected 8–9% membership attrition, aided by favorable rate adjustments and strong medical cost control. Medicare segment profitability is improving, with prescription drug plan margins now expected to be above 3% for the year, up from 2%.
Centene Remains A Buy Heading Into Q3
중립
Zacks Investment Research
그저께
Centene's Gold Card Push Could Ease Costs - But Will Savings Follow?
Centene's nationwide Gold Card program aims to streamline prior authorization and cut administrative costs, but adoption and actual savings will determine its financial impact.
Centene's Gold Card Push Could Ease Costs - But Will Savings Follow?
중립
PRNewsWire
3일 전
PA Health & Wellness Earns National Recognition Among Top Medicaid Health Plans for Second Consecutive Year
MECHANICSBURG, Pa., Oct. 13, 2026 /PRNewswire/ -- PA Health & Wellness, a leading managed care organization in Pennsylvania and a company of Centene Corporation (NYSE: CNC), today announced that it has been recognized among the top 17 Medicaid health plans in the United States by the National Committee for Quality Assurance (NCQA) for the second consecutive year.
PA Health & Wellness Earns National Recognition Among Top Medicaid Health Plans for Second Consecutive Year
중립
PRNewsWire
3일 전
Centene to Launch Nationwide Gold Card Program for Qualifying Providers
ST. LOUIS, Oct. 13, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced it will launch its National Performance-Based Gold Card Program in November 2026. The program, which will initially be available to more than 160,000 qualifying providers nationwide for select outpatient services, is designed to streamline the prior authorization review process while maintaining appropriate clinical and quality standards.
Centene to Launch Nationwide Gold Card Program for Qualifying Providers
긍정적
Zacks Investment Research
4일 전
Centene vs. Molina: Which Managed Care Stock Has More Upside?
CNC's diversified business, improving margins and lower valuation give it an edge over MOH, with stronger earnings prospects and greater upside potential.
Centene vs. Molina: Which Managed Care Stock Has More Upside?
긍정적
Seeking Alpha
6일 전
Centene Q3 2026 Preview: The Quarter Is Easy, The 2027 Bridge Is Not
Centene Corporation has rebounded sharply, with shares up 73% in a year, but now trades near fair value. I expect a Q3 adjusted EPS beat (~$0.25 vs. $0.07–$0.10 consensus), but I see limited upside as 2027 earnings normalization remains the key debate. Medicaid improvement is crucial; HBR progress and membership declines must be closely monitored as policy risks and cost trends remain material.
Centene Q3 2026 Preview: The Quarter Is Easy, The 2027 Bridge Is Not
긍정적
Zacks Investment Research
9일 전
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy?
CNC's improving Medicaid margins, stronger Marketplace profitability and earnings recovery support its valuation, but sustainability remains the key test.
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy?
중립
PRNewsWire
9일 전
Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri
The new partnership will provide eligible members with $0 primary care visits, lab services, and virtual care beginning in 2027 ST. LOUIS, Oct. 7, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC), through Ambetter Health Solutions, today announced a new collaboration with Marathon Health, a leading advanced primary care provider, designed to make primary care easier to access for Ambetter members in select counties across Indiana and Missouri.
Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri
Lightweight Charts™를 사용해 가격 차트를 구현했어요.